{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:10:35Z","timestamp":1760832635494,"version":"build-2065373602"},"reference-count":16,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fragile X syndrome (FXS, OMIM#300624) is the most common inherited cause of X-linked intellectual disability and behavior difficulties. In 99% of cases, it is caused by the pathological expansion (&gt;200 repeats, full mutation -FM) of the CGG trinucleotide located at the 5\u2032 UTR of the FMR1 (Fragile X Messenger Ribonucleoprotein 1) gene, leading to the lack of production of the FMRP. Clinical manifestations are well known in boys but are sometimes overlooked in girls, who may remain underdiagnosed. Premutation (PM) populations (55\u2013200 repeats) may present other medical issues, such as FXPOI or FXTAS. Mosaic conditions, such as a combination of PM and FM lines in the same patient, may lead to milder phenotypes. With the improvement of genetic testing, information regarding the exact number of CGG triplet repeats and methylation status could help explain milder phenotypes in patients who may produce some FMRP. Chromosome X preferential inactivation (XCI) in FXS women can also play a role in clinical severity. We present four non-related families who were followed up in our FXS clinic. Some of their members showed FM on Southern blot, but had milder symptoms than expected. To rule out size mosaicism, a RT-PCR was performed, giving a different and more consistent molecular diagnosis. When mosaicism was not present, methylation status was performed, excluding full methylation. For females, XCI showed preferential inactivation in one case. Revisiting old molecular diagnoses should be considered in clinical practice, especially for patients with a milder phenotype than expected from their molecular reports. This personalized follow up may change their former diagnosis, prognosis, and expectations.<\/jats:p>","DOI":"10.3390\/ijms262010101","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:33:22Z","timestamp":1760632402000},"page":"10101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Follow Up and Genetic Diagnosis Update of FMR1-Related Conditions: A Change in Diagnosis, Prognosis and Expectations"],"prefix":"10.3390","volume":"26","author":[{"given":"Ana","family":"Roche-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Pediatric Neurology Department, Parc Taul\u00ed University Hospital, I3PT-CERCA, UAB, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Ram\u00edrez-Mallafr\u00e9","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Department, Parc Taul\u00ed University Hospital, I3PT-CERCA, UAB, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-724X","authenticated-orcid":false,"given":"Lorena","family":"Joga-Elvira","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Department, Parc Taul\u00ed University Hospital, I3PT-CERCA, UAB, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camen","family":"Manso-Bazus","sequence":"additional","affiliation":[{"name":"Genomic Medicine, Parc Taul\u00ed University Hospital, I3PT-CERCA, UAB, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rubio-Roy","sequence":"additional","affiliation":[{"name":"Neurology Department, Parc Taul\u00ed University Hospital, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Baena-Diez","sequence":"additional","affiliation":[{"name":"Genomic Medicine, Parc Taul\u00ed University Hospital, I3PT-CERCA, UAB, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ciobanu, C.G., Nuc\u0103, I., Popescu, R., Antoci, L.M., Caba, L., Ivanov, A.V., Cojocaru, K.A., Rusu, C., Mihai, C.T., and P\u00e2nzaru, M.C. (2023). Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119206"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Movaghar, A., Page, D., Brilliant, M., and Mailick, M. (2021). Prevalence of Underdiagnosed Fragile X Syndrome in 2 Health Systems. JAMA Netw. Open, 4.","DOI":"10.1001\/jamanetworkopen.2021.41516"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hagerman, R.J., Protic, D., Rajaratnam, A., Salcedo-Arellano, M.J., Aydin, E.Y., and Schneider, A. (2018). Fragile X-Associated Neuropsychiatric Disorders (FXAND). Front. Psychiatry, 9.","DOI":"10.3389\/fpsyt.2018.00564"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Protic, D., Polli, R., Bettella, E., Usdin, K., Murgia, A., and Tassone, F. (2024). Somatic Instability Leading to Mosaicism in Fragile X Syndrome and Associated Disorders: Complex Mechanisms, Diagnostics, and Clinical Relevance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413681"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"St\u00f6ger, R., Genereux, D.P., Hagerman, R.J., Hagerman, P.J., Tassone, F., and Laird, C.D. (2011). Testing the FMR1 Promoter for Mosaicism in DNA Methylation among CpG Sites, Strands, and Cells in FMR1-Expressing Males with Fragile X Syndrome. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023648"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1096-8628(200023)97:3<195::AID-AJMG1037>3.0.CO;2-R","article-title":"Transcription of the FMR1 gene in individuals with fragile X syndrome","volume":"97","author":"Tassone","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ajmg.1320510444","article-title":"Mosaicism in fragile X affected males","volume":"51","author":"Nolin","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ajmg.a.63027","article-title":"Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndrome","volume":"191","author":"Baker","year":"2023","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_9","unstructured":"Hwang, Y.T., Heard, R., and Hunter, M. (2014). 35. Case report: Concurrent occurrence of Fragile X syndrome and Fragile X associated tremor ataxia syndrome due to CGG repeat and methylation mosaicism. J. Clin. Neurosci., 21."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1586\/14737159.2015.1101348","article-title":"Advanced Technologies for the Molecular Diagnosis of Fragile X Syndrome","volume":"15","author":"Tassone","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shou, X.Y., Zhu, Z.W., Jin, H., Hu, J.H., Yan, T.Z., Zhong, Q.Y., Li, W.H., Mao, J.H., Dong, M.Y., and Xu, Q. (2025). Enhanced accuracy and sensitivity in detecting FMR1 CGG repeats: A multicenter evaluation of a novel PCR-capillary electrophoresis assay. World J. Pediatr., 1\u201313.","DOI":"10.1007\/s12519-025-00977-5"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ciaccio, C., Fontana, L., Milani, D., Tabano, S., Miozzo, M., and Esposito, S. (2017). Fragile X syndrome: A review of clinical and molecular diagnoses. Ital. J. Pediatr., 43.","DOI":"10.1186\/s13052-017-0355-y"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jmoldx.2019.11.002","article-title":"Validation of fragile X screening in the newborn population using a fit-for-purpose FMR1 PCR assay system","volume":"22","author":"Lee","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-023-00522-3","article-title":"The application of long-read sequencing in clinical settings","volume":"17","author":"Oehler","year":"2023","journal-title":"Hum. Genomics."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14737159.2017.1377612","article-title":"Size and methylation mosaicism in males with Fragile X syndrome","volume":"17","author":"Jiraanont","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cge.12278","article-title":"FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile","volume":"86","author":"Pugin","year":"2014","journal-title":"Clin. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:18:08Z","timestamp":1760761088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":16,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms262010101"],"URL":"https:\/\/doi.org\/10.3390\/ijms262010101","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}